Sañudo-Peña M C, Force M, Tsou K, McLemore G, Roberts L, Walker J M
Schrier Research Laboratory, Departments of Psychology and Neuroscience, Brown University, Providence, RI 02912, USA.
Zhongguo Yao Li Xue Bao. 1999 Dec;20(12):1121-4.
To determine the dopaminergic system involvement in precipitated cannabinoid withdrawal syndrome.
The dopamine D1 receptor antagonist SCH23390 or the dopamine D2 receptor antagonist sulpiride was administered to rats chronically treated with either delta 9-tetrahydrocannabinol (THC) or vehicle. Subjects were then injected with either SR141716A or vehicle and behavior was observed for 1 h.
Administration of the cannabinoid receptor antagonist SR141716A to animals chronically treated with THC as described by Tsou et al (1995) produced a profound withdrawal syndrome. Treatment with dopamine antagonists did not attenuate cannabinoid precipitated withdrawal syndrome in THC tolerant animals while the agonists increased the syndrome.
It is unlikely that the dopaminergic system plays a major role in mediating the behavioral aspects of the cannabinoid withdrawal syndrome.
确定多巴胺能系统在诱发的大麻素戒断综合征中的作用。
给长期用Δ⁹-四氢大麻酚（THC）或赋形剂处理的大鼠给予多巴胺D1受体拮抗剂SCH23390或多巴胺D2受体拮抗剂舒必利。然后给实验对象注射SR141716A或赋形剂，并观察1小时的行为。
按照邹等人（1995年）所述，给长期用THC处理的动物注射大麻素受体拮抗剂SR141716A会产生严重的戒断综合征。多巴胺拮抗剂治疗并未减轻THC耐受动物中由大麻素诱发的戒断综合征，而激动剂则加重了该综合征。
多巴胺能系统在介导大麻素戒断综合征的行为方面不太可能起主要作用。
